Detalhe da pesquisa
1.
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome.
Tumori;
: 3008916241255485, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38779904
2.
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer.
Chin Clin Oncol;
13(2): 30, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600809
3.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Eur J Cancer;
202: 114006, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38489861
4.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Future Oncol;
2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357801
5.
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib.
Anticancer Drugs;
35(1): 86-88, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37227039
6.
Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
J Thorac Oncol;
18(10): e112-e113, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37758348
7.
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors.
JTO Clin Res Rep;
4(9): 100563, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37745898
8.
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
JCO Precis Oncol;
7: e2300073, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37262392
9.
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.
J Clin Oncol;
41(21): 3700-3711, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37270692
10.
Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
J Neurol;
270(6): 2975-2986, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36800019
11.
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY.
Immunotherapy;
15(2): 85-91, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36628573
12.
Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis.
J Natl Cancer Inst;
115(1): 29-42, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36322815
13.
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
J Clin Oncol;
41(5): 1151-1153, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36318735
14.
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC).
Diagnostics (Basel);
14(1)2023 Dec 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201357
15.
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy.
Cancers (Basel);
14(23)2022 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36497326
16.
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Transl Lung Cancer Res;
11(11): 2216-2229, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519016
17.
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.
Immunotherapy;
14(16): 1329-1340, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382476
18.
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience.
Lung Cancer;
174: 91-96, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36356493
19.
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC).
Int J Mol Sci;
23(18)2022 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36142204
20.
A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab.
Transl Lung Cancer Res;
11(8): 1619-1630, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36090639